Funingana, Ionut-Gabriel http://orcid.org/0000-0002-1197-2652
Bedia, Jacob S. http://orcid.org/0000-0003-1599-8865
Huang, Ying-Wen
Delgado Gonzalez, Antonio http://orcid.org/0000-0002-4760-8174
Donoso, Kenyi
Gonzalez, Veronica D.
Brenton, James D. http://orcid.org/0000-0002-5738-6683
Ashworth, Alan http://orcid.org/0000-0003-1446-7878
Fantl, Wendy J. http://orcid.org/0000-0003-3452-7292
Funding for this research was provided by:
BRCA Foundation
V Foundation for Cancer Research
Ovarian Cancer Academy (W81XWH-12-1-0591)
National Cancer Institute (1R01CA234553, R21CA231280)
Stanford Cancer Institute, Innovation Award 2019
Stanford Cancer Institute, Innovation Award 2021
National Heart, Lung, and Blood Institute (P01HL10879709)
National Institute of Allergy and Infectious Diseases (U19AI057229)
Parker Institute for Cancer Immunotherapy (Bench to Bedside)
CRUK CC
Fundacion Alfonso Martin Escudero
Article History
Received: 31 October 2022
Accepted: 11 December 2022
First Online: 12 January 2023
Declarations
:
: A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation, and Kytarro, a member of the board of Cytomx and Cambridge Science Corporation; is a member of the scientific advisory board of Genentech, GLAdiator, Circle, Bluestar, Earli, Ambagon, Phoenix Molecular Designs, and Trial Library; is a consultant for SPARC, ProLynx, and GSK; receives grant or research support from SPARC and AstraZeneca; and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). JDB is a cofounder and shareholder of Tailor, has had consulting and advisory roles in Astra Zeneca and Clovis Oncology, and has received honoraria from GSK and Astra Zeneca. W.J.F received an honorarium from GSK. All remaining authors have no conflicts of interest to declare.